Immunogenicity and Safety Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine GSK2340274A in Adults 18 to 64 Years of Age.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2015
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 24 Feb 2011 Actual end date (1 Oct 2010) added as reported by ClinicalTrials.gov.
- 24 Feb 2011 Actual initiation date (1 Apr 2010) added as reported by ClinicalTrials.gov.
- 24 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.